Patents Represented by Attorney, Agent or Law Firm Robert J. Cobert
-
Patent number: 6060276Abstract: The present invention provides for nucleic acid sequences that encode novel mammalian receptor polypeptides, designated OCR1. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the MAMMALIAN OCR1 gene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between MAMMALIAN OCR1 and agents that initiate signal transduction through binding to MAMMALIAN OCR1. In a specific embodiment, the MAMMALIAN OCR1 may HUMAN OCR1 or MOUSE OCR1.Type: GrantFiled: January 22, 1998Date of Patent: May 9, 2000Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Piotr J. Masiakowski
-
Patent number: 6022694Abstract: The present invention provides for a screen for a polypeptide ligand that can bind to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor and that can promote a differential function and/or influence the phenotype, such as growth and/or proliferation, of cells that bear the receptor. The present invention also provides a method of screening for a molecule capable of competing with collagen for binding to the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor comprising contacting a sample suspected of containing the molecule with the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor in the presence of collagen under conditions in which the collagen is capable of binding to the extracellular domain and detecting binding of the molecule to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor extracellular domain. The invention further contemplates the utilization of collagen to support the growth, survival, or differentiation of Tyro-10 (DDR-2) or NEP (DDR-1) expressing cells.Type: GrantFiled: December 29, 1997Date of Patent: February 8, 2000Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Czeslaw Radziejewski, Ajay Shrivastava, George D. Yancopoulos
-
Patent number: 5879672Abstract: The present invention provides for an isolated nucleic acid molecule encoding human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds human TIE-2 ligand. The invention also provides an antibody which specifically binds human TIE-2 ligand. The invention further provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization and a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor.Type: GrantFiled: December 2, 1994Date of Patent: March 9, 1999Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Thomas H. Aldrich, George D. Yancopoulos
-
Patent number: 5851797Abstract: The present invention provides for an isolated nucleic acid molecule encoding TIE ligand-3. In addition, the invention provides for a receptorbody which specifically binds TIE ligand-3. The invention also provides an antibody which specifically binds TIE ligand-3. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: June 19, 1996Date of Patent: December 22, 1998Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David M. Valenzuela, Pamela F. Jones, George D. Yancopoulos
-
Patent number: 5846935Abstract: Modified ciliary neurotrophic factors and methods for their production and therapeutic use. Also described is a method of screening for novel therapeutic proteins by determining altered electrophoretic binding properties.Type: GrantFiled: September 19, 1994Date of Patent: December 8, 1998Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Nikos Panayotatos
-
Patent number: 5821124Abstract: Novel dorsal growth inducing factors, complexes including the factors, and DNA or RNA coding sequences for the factors are described. Hybridoma cell lines and antibodies that bind to the dorsal growth inducing factor noggin, having the amino acid sequence set forth in SEQ ID NO:2, are also described.Type: GrantFiled: June 7, 1995Date of Patent: October 13, 1998Assignees: Regeneron Pharmaceuticals, Inc., Regents of Univ. of CaliforniaInventors: David M. Valenzuela, George D. Yancopoulos, Richard M. Harland, William C. Smith
-
Patent number: 5814478Abstract: The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated and purified polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.Type: GrantFiled: May 10, 1996Date of Patent: September 29, 1998Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David M. Valenzuela, David J. Glass, David C. Bowen, George D. Yancopoulos
-
Patent number: 5656473Abstract: The present invention provides for a gene, designated as dmk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the dmk gene product. The present invention also provides for diagnostic and therapeutic methods based on the interaction between Dmk and agents that initiate signal transduction through binding to Dmk.Type: GrantFiled: January 19, 1995Date of Patent: August 12, 1997Assignee: Regeneron Pharmaceuticals, Inc.Inventors: David M. Valenzuela, Eduardo A. Rojas
-
Patent number: 5650490Abstract: The present invention provides for an isolated nucleic acid molecule encoding human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds human TIE-2 ligand. The invention also provides an antibody which specifically binds human TIE-2 ligand. The invention further provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization and a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor.Type: GrantFiled: January 17, 1995Date of Patent: July 22, 1997Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Pamela F. Jones, George D. Yancopoulos
-
Patent number: 5643755Abstract: The present invention provides for TIE-2 ligand substantially free of other proteins. The invention also provides for an isolated nucleic acid molecule encoding TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds TIE-2 ligand. The invention also provides an antibody which specifically binds TIE-2 ligand. The invention further provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization and a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor.Type: GrantFiled: October 7, 1994Date of Patent: July 1, 1997Assignee: Regeneron Pharmaceuticals Inc.Inventors: Samuel Davis, Thomas Aldrich, George D. Yancopoulos
-
Patent number: 5521073Abstract: The present invention provides for an isolated nucleic acid molecule encoding human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds human TIE-2 ligand. The invention also provides an antibody which specifically binds human TIE-2 ligand. The invention further provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization and a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor.Type: GrantFiled: October 27, 1994Date of Patent: May 28, 1996Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Thomas H. Aldrich, George D. Yancopoulos
-
Patent number: 5262523Abstract: Antibodies reactive with normal and oncogenic forms of the ras p21 protein. The antibodies are secreted by hybridomas obtained by immunizing mice with the Ha ras p21 protein containing the arginine mutation at position 12 of the protein. The antibodies and immunoreactive fragments thereof of useful for detection, diagnosis, quantitation, staging and classification of normal and activated ras p21s in normal tissues, malignant and premalignant lesions.Type: GrantFiled: November 27, 1991Date of Patent: November 16, 1993Assignee: Oncogene Science, Inc.Inventor: Walter P. Carney
-
Patent number: 5217896Abstract: This invention provides a monoclonal antibody which specifically forms a complex with amino acids 1-87 of PTHLP which does not form a complex with amino acids 1-34 of PTHLP, and which forms a complex with the epitope to which any of the monoclonal antibodies produced by the hybridomas 212-10.7, (ATCC Accession No. HB9930), 199-999 (ATCC Accession No. HB9929), 199-278 (ATCC Accession No. HB9931), is directed.This invention further provides methods of detecting PTHLP and of diagnosing and treating humoral hypercalcemia of malignancy.Type: GrantFiled: December 30, 1988Date of Patent: June 8, 1993Assignee: Oncogene Science, Inc.Inventors: Steven P. Kramer, David M. Valenzuela, Frederick H. Reynolds, Jr., John M. Sorvillo